@article {Trotman:2016:1040-872X:366,
title = "Delayed puberty in the female patient",
journal = "Current Opinion in Obstetrics and Gynecology",
parent_itemid = "infobike://wk/coogy",
publishercode ="wk",
year = "2016",
volume = "28",
number = "5",
publication date ="2016-10-01T00:00:00",
pages = "366-372",
itemtype = "ARTICLE",
issn = "1040-872X",
eissn = "1473-656X",
url = "https://www.ingentaconnect.com/content/wk/coogy/2016/00000028/00000005/art00007",
doi = "doi:10.1097/GCO.0000000000000303",
keyword = "constitutional delay of growth and puberty, delayed puberty, sex steroid replacement therapy",
author = "Trotman, Gylynthia E.",
abstract = "
Purpose of review
The purpose is to review current recommendations for the evaluation and management of delayed puberty in the female patient.
Recent findings
Kisspeptin activation has emerged as an important factor for initiation of pubertal development.
Causes of delayed puberty can be considered in four main categories: constitutional delay of growth and puberty, hypergonadotropic hypogonadism, permanent hypogonadotropic hypogonadism, and transient/functional hypogonadism. The most common cause of delayed puberty is constitutional delay
of growth and puberty; however, consistent differentiation from idiopathic hypogonadotropic hypogonadism remains challenging. Initial assessment with broad spectrum testing in an otherwise healthy adolescent is often of low clinical value. Treatment is aimed at the underlying cause of delayed
puberty whenever possible and individualized to the patient.Summary
Understanding the factors that contribute to delayed puberty and a thoughtful evaluation, structured to the patient, is important to identify the cause of delayed puberty and
prevent unnecessary and often expensive investigations. Insuring appropriate pubertal progression, optimizing height and bone health, as well as preservation of psychosocial well-being are the ultimate goals of management of delayed puberty.",
}